Literature DB >> 21251688

Characterization of species C human adenovirus serotype 6 (Ad6).

Eric A Weaver1, Mathew L Hillestad, Reeti Khare, Donna Palmer, Philip Ng, Michael A Barry.   

Abstract

Adenovirus serotype (Ad5) is the most studied Ad. Ad1, 2, and 6 are also members of species C Ad and are presumed to have biologies similar to Ad5. In this work, we have compared the ability of Ad1, 2, 5, and 6 to infect liver and muscle after intravenous and intramuscular injection. We found that Ad6 was surprisingly the most potent at liver gene delivery and that Ad1 and Ad2 were markedly weaker than Ad5 and 6. To understand these differences, we sequenced the Ad6 genome. This revealed that the Ad6 fiber protein is surprisingly three shaft repeats shorter than the others which may explain differences in virus infectivity in vitro, but not in the liver. Comparison of hexon hypervariable regions (HVRs) suggests that the higher transduction by Ad5 and 6 as compared to Ad1 and 2 may be related to differences in charge and length.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21251688      PMCID: PMC3056908          DOI: 10.1016/j.virol.2010.10.041

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  28 in total

1.  Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity.

Authors:  Angelique A C Lemckert; Shawn M Sumida; Lennart Holterman; Ronald Vogels; Diana M Truitt; Diana M Lynch; Anjali Nanda; Bonnie A Ewald; Darci A Gorgone; Michelle A Lifton; Jaap Goudsmit; Menzo J E Havenga; Dan H Barouch
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

2.  Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity.

Authors:  Dmitry M Shayakhmetov; Anuj Gaggar; Shaoheng Ni; Zong-Yi Li; André Lieber
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

3.  Atomic structure of human adenovirus by cryo-EM reveals interactions among protein networks.

Authors:  Hongrong Liu; Lei Jin; Sok Boon S Koh; Ivo Atanasov; Stan Schein; Lily Wu; Z Hong Zhou
Journal:  Science       Date:  2010-08-27       Impact factor: 47.728

4.  PEGylated helper-dependent adenoviral vectors: highly efficient vectors with an enhanced safety profile.

Authors:  M A Croyle; H T Le; K D Linse; V Cerullo; G Toietta; A Beaudet; L Pastore
Journal:  Gene Ther       Date:  2005-04       Impact factor: 5.250

5.  Protection against Mucosal SHIV Challenge by Peptide and Helper-Dependent Adenovirus Vaccines.

Authors:  Eric A Weaver; Pramod N Nehete; Bharti P Nehete; Stephanie J Buchl; Donna Palmer; David C Montefiori; Philip Ng; K Jagannadha Sastry; Michael A Barry
Journal:  Viruses       Date:  2009-12-01       Impact factor: 5.048

6.  Neutralizing antibodies against 33 human adenoviruses in normal children in Rome.

Authors:  E D'Ambrosio; N Del Grosso; A Chicca; M Midulla
Journal:  J Hyg (Lond)       Date:  1982-08

7.  Infection and killing of multiple myeloma by adenoviruses.

Authors:  Julien S Senac; Konstantin Doronin; Stephen J Russell; Diane F Jelinek; Philip R Greipp; Michael A Barry
Journal:  Hum Gene Ther       Date:  2010-02       Impact factor: 5.695

8.  Latent species C adenoviruses in human tonsil tissues.

Authors:  C T Garnett; G Talekar; J A Mahr; W Huang; Y Zhang; D A Ornelles; L R Gooding
Journal:  J Virol       Date:  2008-12-24       Impact factor: 5.103

9.  Modification of adenoviral vectors with polyethylene glycol modulates in vivo tissue tropism and gene expression.

Authors:  Sean E Hofherr; Elena V Shashkova; Eric A Weaver; Reeti Khare; Michael A Barry
Journal:  Mol Ther       Date:  2008-05-06       Impact factor: 11.454

10.  Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes.

Authors:  Alan L Parker; Simon N Waddington; Campbell G Nicol; Dmitry M Shayakhmetov; Suzanne M Buckley; Laura Denby; Geoffrey Kemball-Cook; Shaoheng Ni; Andre Lieber; John H McVey; Stuart A Nicklin; Andrew H Baker
Journal:  Blood       Date:  2006-06-20       Impact factor: 22.113

View more
  22 in total

1.  Generation of a Kupffer cell-evading adenovirus for systemic and liver-directed gene transfer.

Authors:  Reeti Khare; Shannon M May; Francesco Vetrini; Eric A Weaver; Donna Palmer; Amanda Rosewell; Nathan Grove; Philip Ng; Michael A Barry
Journal:  Mol Ther       Date:  2011-04-19       Impact factor: 11.454

2.  Comparison of the Life Cycles of Genetically Distant Species C and Species D Human Adenoviruses Ad6 and Ad26 in Human Cells.

Authors:  Mallory A Turner; Sumit Middha; Sean E Hofherr; Michael A Barry
Journal:  J Virol       Date:  2015-09-30       Impact factor: 5.103

3.  Identification of adenovirus serotype 5 hexon regions that interact with scavenger receptors.

Authors:  Reeti Khare; Vijay S Reddy; Glen R Nemerow; Michael A Barry
Journal:  J Virol       Date:  2011-12-07       Impact factor: 5.103

4.  Pathology in Permissive Syrian Hamsters after Infection with Species C Human Adenovirus (HAdV-C) Is the Result of Virus Replication: HAdV-C6 Replicates More and Causes More Pathology than HAdV-C5.

Authors:  Ann E Tollefson; Baoling Ying; Jacqueline F Spencer; John E Sagartz; William S M Wold; Karoly Toth
Journal:  J Virol       Date:  2017-04-28       Impact factor: 5.103

5.  Breaking tolerance with engineered class I antigen-presenting molecules.

Authors:  Christopher A Parks; Kalli R Henning; Kevin D Pavelko; Michael J Hansen; Virginia P Van Keulen; Brendan K Reed; Jennifer D Stone; Adam G Schrum; Diana Gil; David M Kranz; Andrew J Bordner; Michael A Barry; Larry R Pease
Journal:  Proc Natl Acad Sci U S A       Date:  2019-02-06       Impact factor: 11.205

6.  Ex Vivo and In Vivo CD46 Receptor Utilization by Species D Human Adenovirus Serotype 26 (HAdV26).

Authors:  Jack R Hemsath; A Manuel Liaci; Jeffrey D Rubin; Brian J Parrett; Shao-Chia Lu; Tien V Nguyen; Mallory A Turner; Christopher Y Chen; Karolina Cupelli; Vijay S Reddy; Thilo Stehle; M Kathryn Liszewski; John P Atkinson; Michael A Barry
Journal:  J Virol       Date:  2021-11-17       Impact factor: 6.549

7.  Circulating antibodies and macrophages as modulators of adenovirus pharmacology.

Authors:  Reeti Khare; Matthew L Hillestad; Zhili Xu; Andrew P Byrnes; Michael A Barry
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

8.  IIIa deleted adenovirus as a single-cycle genome replicating vector.

Authors:  Catherine M Crosby; Michael A Barry
Journal:  Virology       Date:  2014-07-02       Impact factor: 3.616

Review 9.  Retargeting adenoviruses for therapeutic applications and vaccines.

Authors:  Michael A Barry; Jeffrey D Rubin; Shao-Chia Lu
Journal:  FEBS Lett       Date:  2020-02-03       Impact factor: 4.124

Review 10.  Advances and future challenges in adenoviral vector pharmacology and targeting.

Authors:  Reeti Khare; Christopher Y Chen; Eric A Weaver; Michael A Barry
Journal:  Curr Gene Ther       Date:  2011-08       Impact factor: 4.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.